Severe vasospastic reactions (ergotism) during prophylactic administration of heparin-dihydroergotamine.
H
H
Bounameaux
P A
PA
Schneider
A
A
Mossaz
P
P
Suter
H
H
Vasey
D000293:Adolescent; D000328:Adult; D004087:Dihydroergotamine / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight; D006801:Humans; D007511:Ischemia / Q000139:chemically induced*; D007866:Leg / Q000098:blood supply*; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000517:prevention & control*; D014661:Vasoconstriction / Q000187:drug effects*
D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight; C031388:heparin-dihydergot; D004087:Dihydroergotamine; D006493:Heparin